Our pipeline

HER-2 PHASE 1 BREAST IMAGING COMPLETE

Phase 1 imaging has been completed on 33 patients with Technetium-99m in Shanghai and Germany

• Non-invasive and demonstrated safety
• Accumulation / high uptake in target within 2 hours post injection
• Acceptable biodistribution and dosimetry (renal protection can be achieved by standard pre-injection of gelufusin/amino acids mixture)
• Shows clear intra and inter-tumoural heterogeneity of HER-2 expression
• Provide more accurate and informative information on HER-2 cancers in comparison to existing IHC / FISH detections from biopsy samples
• Potential to be used for whole body assessment and treatment of HER-2+ cancers with different medical radioisotopes

HER-2 PHASE 1 BREAST THERAPEUTIC COMMENCING

• Phase 1 therapeutic about to launch in late stage HER-2+ breast cancer in Germany with Re-188 and Lu-177
• Can be easily adopted as a therapeutic with Lu-177 or Ac-225
• High probability of success as a therapeutic agent
• Patient safety data
• Same targeting as imaging but just change of war-head ( Tc-99m to Re-188, or Ga-68 to Lu-177 )
• Re- and Tc- structural and reaction chemistry is the “same” – easy conversion
• Apply to patients with good images and dosimetry – see then treat

PD-L1 PHASE 1 NON SMALL CELL LUNG CANCER IMAGING HAS BEEN COMPLETED ON 40 PATIENTS

• PD-L1 is a pan-cancer biomarker and immuno-checkpoint blockers are becoming the most important treatment of multiple cancers
• Imaging technology is licensed to Lantheus for research collaborations in diagnostic imaging
• Worldwide exclusive license to Radioharm Theranostics for therapeutic use
• Imaging done on 40 NSCLC patients in Shanghai General and at Kings College London
• Approved for Phase 2 Imaging Clinical Trial by MHRA
• DMF for Imaging filed with FDA in US
• Easily adopted for therapeutic use
• High probability of success as therapeutic agent
• Patients safety data; same cold kit as imaging but just change of war-head
• Apply to patients with good images – see then treat

Pivalate Phase 1

Imaging complete in cerebral metastases, glioma, kidney, solid tumors

Pivalate Phase 2

In cerebral metastases, glioma interim positive data summary below

AVβ6 BEST-IN-CLASS : PHASE 1a COMMENCED

Biodistribution generally (Healthy subject comparison)